Metastatik pankreas kanserleri olan hastalarda nötrofil lenfosit oranı, trombosit inksleri ve sistemik immün imflamasyon indeksi ile klinik, patolojik ve prognostik faktörler arasındaki ilişkinin değerlendirilmesi
Yükleniyor...
Dosyalar
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Trakya Üniversitesi, Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Pankreas kanseri en agresif kanserlerden birisidir. Bu çalışmada, lokal immün yanıtı ve sistemik inflamasyonu daha iyi yansıtabilecek ve klinik olarak mevcut periferik nötrofil, lenfosit ve trombosit sayımlarına dayanan entegre belirteçlerin, pankreas kanserlerinde tedaviye yanıt ve sağkalım ile ilişkili olup olmadığını saptamayı amaçladık. 1 Ocak 2012 ile 1 Eylül 2019 tarihleri arasında Trakya Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji Bilim Dalında metastatik pankreas adenokarsinom tanısı alan ve kemoterapi rejimi uygulanan 75 hastanın klinik, patolojik ve prognostik özelliklerini retrospektif olarak değerlendirdik. Sistemik inflamasyon belirteçlerinin literatürde fikir birliğine varılmış eşik değerleri olmadığı için, çalışmamızda eşik değerler olarak kullanılmak üzere medyan değerleri belirledik. Çalışmamızda; NLO medyan değerin altında (<3) olan hastalarda genel sağkalım süresinin daha uzun olduğunu tespit ettik. (p=0,001). Yüksek trombosit sayısının (?235.10 3 ) daha uzun progresyonsuz sağkalım ile ilişkili olduğunu (p=0,02) ve benzer şekilde yüksek PCT’nin (?0,22) daha uzun progresyonsuz sağkalım ile ilişkili olduğunu belirledik (p=0,01). ECOG skoru 0-1 olan hastaların genel sağkalım süresinin ECOG skoru 2 olan hastalara göre daha uzun olduğunu saptadık (p:0,003). Birinci seri hastalık kontrolü sağlanan hastalarda genel sağkalım süresinin hastalık kontrolü sağlanamayan hastalara göre daha uzun olduğunu belirledik (p=0.002). Çalışmamız, metastatik pankreas kanser tanılı hastalarda NLO’nun genel sağkalımı predikte eden bağımsız bir belirteç olabileceğini ve progresyonsuz sağkalımın trombosit sayısı ve PCT ile ilişkili olduğunu göstermiştir.
Pancreatic cancer is one of the most aggressive cancers. In this study, we aimed to determine whether integrated markers that better reflect local immune response and systemic inflammation and based on clinically available peripheral neutrophil, lymphocyte and platelet counts are associated with treatment response and survival in pancreatic cancers. We retrospectively evaluated the clinical, pathological and prognostic features of 75 patients who were diagnosed with metastatic pancreatic adenocarcinoma and who treated between January 1, 2012 and September 1, 2019 at Trakya University Medical Faculty, Medical Oncology Department. Since systemic inflammation markers did not have agreed threshold values in the literature, we determined the median values to be used as threshold values in our study. In our study; We found that the overall survival was longer in patients with lower than NLO median value (<3) (p=0.001). We determined that the high platelet count (?235.10³) was related to longer progression-free survival (p=0.02) and similarly, higher PCT (?0.22) was related to longer progression-free survival (p=0.01). We found that the overall survival of patients with an ECOG score of 0-1 was longer than that of patients with an ECOG score of 2 (p= 0.003). We determined that the overall survival in patients with the first series of disease control was longer than those without disease control (p=0.002). Our study showed that NLO may be an independent marker predicting overall survival in patients with metastatic pancreatic cancer, and progression-free survival is associated with platelet count and PCT.
Pancreatic cancer is one of the most aggressive cancers. In this study, we aimed to determine whether integrated markers that better reflect local immune response and systemic inflammation and based on clinically available peripheral neutrophil, lymphocyte and platelet counts are associated with treatment response and survival in pancreatic cancers. We retrospectively evaluated the clinical, pathological and prognostic features of 75 patients who were diagnosed with metastatic pancreatic adenocarcinoma and who treated between January 1, 2012 and September 1, 2019 at Trakya University Medical Faculty, Medical Oncology Department. Since systemic inflammation markers did not have agreed threshold values in the literature, we determined the median values to be used as threshold values in our study. In our study; We found that the overall survival was longer in patients with lower than NLO median value (<3) (p=0.001). We determined that the high platelet count (?235.10³) was related to longer progression-free survival (p=0.02) and similarly, higher PCT (?0.22) was related to longer progression-free survival (p=0.01). We found that the overall survival of patients with an ECOG score of 0-1 was longer than that of patients with an ECOG score of 2 (p= 0.003). We determined that the overall survival in patients with the first series of disease control was longer than those without disease control (p=0.002). Our study showed that NLO may be an independent marker predicting overall survival in patients with metastatic pancreatic cancer, and progression-free survival is associated with platelet count and PCT.
Açıklama
Anahtar Kelimeler
Metastatik Pankreas Kanseri, Sağkalım, Nötrofil Lenfosit Oranı, Trombosit, PCT, Metastatic Pancreatic Cancer, Survival, Neutrophil Lymphocyte Ratio, Platelet
